Trial
NCT04044378
Famitinib Plus Camrelizumab & Famitinib Alone & Famitinib Plus Ifosfamide in Advanced Osteosarcoma
Phase IWITHDRAWNSAFETYConfidence: MEDIUM
Sponsor
Peking University People's Hospital
Collaborators
Peking University Shougang Hospital; Jiangsu HengRui Medicine Co., Ltd.
Condition
Effect of Drugs
Intervention
Famitinib
Why stopped
toxicity
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2020-05-19